THERAPEUTIC TARGETS FOR HUNTINGTON'S DISEASE

被引:0
|
作者
Sorbera, L. A. [1 ]
Dulsat, C. [1 ]
Rosa, E. [1 ]
机构
[1] Thomson Reuters, Barcelona 08025, Spain
关键词
Huntington's disease; Neurodegeneration; Targets; Therapeutic intervention; TRANSGENIC MOUSE MODEL; OXIDATIVE STRESS; MECHANISMS; DOPAMINE; TETRABENAZINE; PHARMACOLOGY; RECEPTORS; SEROTONIN; DISCOVERY; ADENOSINE;
D O I
10.1358/dof.2012.037.06.1811775
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disorder characterized by chorea and dystonia, as well as cognitive, emotional, behavioral and psychiatric abnormalities. To date, a cure for the disease remains elusive, although there are products available that provide symptomatic relief. Unfortunately, several of these agents can be associated with potentially serious adverse effects and none cure the disease. Examples include antipsychotics and benzodiazepines to improve chorea and psychiatric symptoms, beta-adrenoceptor blockers for controlling aggressiveness and selective serotonin reuptake inhibitors (SSRIs) for depressive symptoms. However, due to the numerous and complex mechanisms involved in the selective neurodegeneration seen in HD, no potential pharmacotherapy has demonstrated efficacy in curing or slowing disease progression to date. Researchers actively continue to search for effective treatments for HD, with special attention given to the identification of novel targets for therapeutic intervention. This article presents those drug targets that are currently under active investigation for the treatment of HD.
引用
收藏
页码:437 / 443
页数:7
相关论文
共 50 条
  • [1] Huntington's Disease Therapeutic Targets Found
    不详
    [J]. US PHARMACIST, 2014, 39 (03) : 50 - 50
  • [2] Novel therapeutic targets for Huntington's disease
    Hannan, AJ
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) : 639 - 650
  • [3] Phosphodiesterases as Therapeutic Targets for Huntington's Disease
    Fusco, Francesca R.
    Giampa, Carmela
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (03) : 365 - 377
  • [4] Molecular Targets and Therapeutic Strategies in Huntington's Disease
    Cristina Rego, A.
    de Almeida, Luis Pereira
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (04) : 361 - 381
  • [5] FROM BASIC MECHANISMS TO THERAPEUTIC TARGETS IN HUNTINGTON'S DISEASE
    Thompson, L. M.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 13 - 13
  • [6] Validation of candidate therapeutic targets for Huntington's disease in drosophila
    Campesan, S.
    Kyriacou, C. P.
    Giorgini, F.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 : A5 - A6
  • [7] IDENTIFICATION AND VALIDATION OF CANDIDATE THERAPEUTIC TARGETS FOR HUNTINGTON'S DISEASE
    Clapp, J.
    Giorgini, F.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A11 - A11
  • [8] Epigenetic modifications as novel therapeutic targets for Huntington's disease
    Wang, Fengli
    Fischhaber, Paula L.
    Guo, Caixia
    Tang, Tie-Shan
    [J]. EPIGENOMICS, 2014, 6 (03) : 287 - 297
  • [9] Hypothalamic pathology and endocrine changes as therapeutic targets for Huntington's disease
    Petersén, Å
    Björkqvist, M
    Gil, J
    Popovic, N
    Norlén, P
    Mulder, H
    Brundin, P
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [10] METALLOTHIONEINS AND COPPER METABOLISM: CANDIDATE THERAPEUTIC TARGETS IN HUNTINGTON'S DISEASE
    Wyttenbach, A.
    Hands, S.
    Mason, R.
    Sajjad, M. U.
    Giorgini, F.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A3 - A3